Trials / Terminated
TerminatedNCT02742090
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Umbralisib | Umbralisib was administered as a tablet(s), orally once daily. |
Timeline
- Start date
- 2016-04-21
- Primary completion
- 2021-06-10
- Completion
- 2021-06-10
- First posted
- 2016-04-18
- Last updated
- 2024-07-03
- Results posted
- 2024-07-03
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02742090. Inclusion in this directory is not an endorsement.